Non-dialysis kidney patients benefit greatly from COVID-19 vaccination

A new study shows that non-dialysis kidney patients who are vaccinated have a significantly reduced risk of COVID-19 infection – up to 78% with three vaccine doses – compared to their non-vaccinated time period. The results, which also show that vaccines significantly reduce risk of hospitalization and death from the virus in this population, were published this September in Kidney International.

Read More

Updated clinical tool assesses risk of IgA nephropathy progression over time

In an important advance for precision medicine, researchers have refined a tool used to predict which people living with IgA nephropathy are likely to experience disease progression. The original prediction tool is used at the time when patients first receive their diagnosis, but this second version can be used at the one- or two-year mark after diagnosis to better inform ongoing treatment decisions.

Read More

Researcher profile: Dr. Mike Bevilacqua

Dr. Mike Bevilacqua is a Fraser Health nephrologist based in Surrey, British Columbia, who has dedicated the past seven years of his work life as a health care provider for people living with kidney disease. But his interests also extend to driving systems-level changes in the delivery of kidney care, and he has taken on numerous quality improvement and research initiatives to reach these goals.

Read More

Staff profile: Catherine Turner, Indigenous Liaison Manager, Can-SOLVE CKD Network

Historically, research has been done unilaterally on, rather than with, Indigenous people in Canada, which has exacerbated health inequities. But some people are working hard to change this status quo, including Catherine Turner.

Read More